Editor: Shazia Anjum

Frontiers in Clinical Drug Research – Diabetes and Obesity

Volume 7

eBook: US $79 Special Offer (PDF + Printed Copy): US $133
Printed Copy: US $93
Library License: US $316
ISSN: 2467-9607 (Print)
ISSN: 2352-3220 (Online)
ISBN: 978-981-5123-59-3 (Print)
ISBN: 978-981-5123-58-6 (Online)
Year of Publication: 2023
DOI: 10.2174/97898151235861230701


Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.

The seventh volume of this series features 6 reviews on diabetes related topics for both medical specialists and pharmacologists.

- Clinical and diagnostic implications of glycated albumin in diabetes mellitus.

- Development of novel therapeutic groups and bioactive compounds from herbs for diabetes management

- Aspartame as a sugar substitute

- Mental health, adherence, and self-management among children with diabetes

- Cardioprotective effects of new generation anti-diabetic and lipid-lowering agents

- Epidemiology, pathophysiology, and treatment of diabesity


Medical specialists (endocrinology, diabetology, nutrition), pharmacologists and clinical researchers


Causes of diabetes are so complex but type II diabetes is directly linked with obesity at any time of your age particularly if you have excessive fats around your tummy. Obesity triggers your body’s metabolism which causes fat tissues to release fats into your blood that directly affect insulin response and make you insulin sensitive- that’s why obesity causes prediabetes. In order to understand this complex pathological disorder in our body and thereafter solutions to surpass this challenge, volume 7 of our eBook series is dedicated to cutting-edge articles on Diabetes or Obesity. The update can be found in the first chapter of this present volume that non-enzymatic glycation of proteins, lipids, and fatty acids speeds up due to persistent hyperglycemia and eventually causes associated secondary complications in diabetes.

The authors in the second chapter describe the current strategies of new drugs for diabetes management. For example, the development of novel therapeutic groups such as amylin analogs, incretin mimetics, GIP analogs, active peroxisome proliferator receptors, and dipeptidyl peptidase-4 inhibitors and as well as bioactive compounds from herbs.

The third chapter of this series deals with the debatable topic of using aspartame for T2D patients. More research is still needed to establish the pathological role of aspartame use in T2D.

Chapter four of this volume covers the research to investigate the psychological characteristics and adherence of children and adolescents with Type 2 diabetes. A joint venture of the Faculty of Medicine and Faculty of Arts has developed that mapping mental health and various therapeutic procedures, as well as their positive and negative effects, are of paramount importance for both diabetes and obesity.

The fifth chapter of this volume is about the clinical trials of new-generation anti-diabetic and lipid-lowering agents that also have simultaneously cardioprotective effects.

The sixth chapter of this volume describes that the kidneys are a vulnerable target of diabesity. In this chapter, the epidemiology, pathophysiology, and treatment of diabesity–induced kidney disease are discussed. The special focus on the therapeutic targets and pharmacological management of diabesity-related kidney diseases is described herein.

I hope that the current volume of this series will provide updated information about the recent developments in Diabetes & Obesity treatment for interested researchers and pharmaceutical scientists. I would like to thank the editorial staff, particularly Mr. Mahmood Alam (Director Publications) and Ms. Asma Ahmed (Senior Manager Publications) for their dedicated efforts and the hard work.

Shazia Anjum
Institute of Chemistry
The Islamia University of Bahawalpur